Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODAC Calls For Additional EPO Trials To Support Continued Use In Oncology

This article was originally published in The Pink Sheet Daily

Executive Summary

In the absence of data on approved therapeutic target, panel advises adding warnings from signals in off-label use to label.

You may also be interested in...



Access To ESRD Drugs Under Bundled Medicare Payments Concerns GAO

The Government Accountability Office is issuing a cautionary note that Medicare's upcoming prospective payment system for end-stage renal disease might impair access to drugs for some demographic groups

Access To ESRD Drugs Under Bundled Medicare Payments Concerns GAO

The Government Accountability Office is issuing a cautionary note that Medicare's upcoming prospective payment system for end-stage renal disease might impair access to drugs for some demographic groups

Amgen’s Aranesp, Procrit CIA Indications Okay For Incurable Cancers - ODAC

Panel suggests new label saying the chemotherapy-induced anemia treatments are not indicated for patients with curable cancers, breast cancer or head and neck tumors.

Related Content

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel